EUVIMEDEUVIMED entdecken
Crossref

Psoriasis and Malignancy

Ron Vender

Canadian Dermatology Today · 20.03.2026 · 5-9

DOI: 10.58931/cdt.2026.71156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Dermatology Today, online erschienen am 20.03.2026. Verfasst von Ron Vender.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KEY TAKEAWAYS: • Psoriasis confers a modest overall increase in malignancy risk, concentrated in NMSC and selected lymphoid cancers, and amplified by disease severity and cumulative PUVA/systemic exposure. • Chronic systemic inflammation and, in some contexts, therapy-related immunomodulation jointly shape cancer risk in psoriasis, rather than biologic treatment being uniformly carcinogenic. • Modern biologic and targeted therapies—including IL-17 and IL-23 inhibitors, as well as PDE4 and TYK2 inhibitors—generally show no clear increase in overall malignancy or recurrence risk, though ongoing pharmacovigilance and individualized oncology input remain crucial. • Management should be multidisciplinary and risk-adapted, combining effective psoriasis control with tailored cancer surveillance and aggressive modification of lifestyle risk factors (smoking, alcohol, obesity, UV exposure).

Zitieren

APA

Vender, R. (2026). Psoriasis and Malignancy. Canadian Dermatology Today, 5-9. https://doi.org/10.58931/cdt.2026.71156

Vancouver

Vender R. Psoriasis and Malignancy. Canadian Dermatology Today. 2026:5-9. doi:10.58931/cdt.2026.71156

BibTeX
@article{Vender2026,
  author = {Vender, Ron},
  title = {Psoriasis and Malignancy},
  journal = {Canadian Dermatology Today},
  year = {2026},
  pages = {5--9},
  doi = {10.58931/cdt.2026.71156}
}
Kostenlos starten →